{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-064850","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2026-05-21T11:03:16+00:00","discovered_at":"2026-05-21T11:05:00.307287+00:00","generated_at":"2026-05-21T11:06:03.597926+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Protalix BioTherapeutics files corporate presentation; no material new information","bullets":["Filing reports posting of May 2026 corporate presentation to company website under Item 7.01.","Exhibit 99.1 contains only title slides with general corporate description and date change from June 2024 to May 2026.","No financial results, guidance updates, or operational milestones disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-064850","json":"https://secwatch.observer/filing/0001104659-26-064850.json","markdown":"https://secwatch.observer/filing/0001104659-26-064850.md","text":"https://secwatch.observer/filing/0001104659-26-064850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926064850/0001104659-26-064850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926064850/plx-20260521x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T11:06:03.597926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}